<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value"/></p>
<p>纳斯达克 GM:FLGT 1 年股价与公允价值</p>
<p>探索 Fulgent Genetics 的社区公允价值并选择您的观点</p>
<p>当美国医疗行业近一半的公司市销率（或称&#34;P/S&#34;）低于 1 倍时，您可能会考虑 <strong>Fulgent Genetics, Inc.</strong>（NASDAQ:FLGT）作为一个潜在的避开对象，因为其市销率为 2.1 倍。然而，市销率可能高是有原因的，需要进一步调查以确定其是否合理。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 Fulgent Genetics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719"/></p>
<p>纳斯达克 GM:FLGT 市销率与行业比较 2025 年 8 月 6 日</p>
<h3>Fulgent Genetics 的表现如何</h3>
<p>最近一段时间，Fulgent Genetics 的表现并不理想，因为其收入增长速度低于大多数其他公司。也许市场预计未来的收入表现将会逆转，这提升了市销率。然而，如果情况并非如此，投资者可能会发现自己为该股票支付了过高的价格。</p>
<p>如果您想了解分析师对未来的预测，您应该查看我们关于 Fulgent Genetics 的 <strong>免费</strong> 报告。</p>
<h2>Fulgent Genetics 的收入增长预测是否足够？</h2>
<p>为了证明其市销率的合理性，Fulgent Genetics 需要实现超过行业的显著增长。</p>
<p>回顾过去一年的收入增长，公司实现了 4.3% 的可观增长。然而，遗憾的是，收入与三年前相比总共下降了 67%，这令人失望。因此，不幸的是，我们必须承认公司在这段时间内未能很好地实现收入增长。</p>
<p>展望未来，覆盖该公司的三位分析师的估计显示，收入在明年应增长 11%。而行业仅预测增长 7.7%，公司有望实现更强的收入结果。</p>
<p>考虑到这一点，理解为什么 Fulgent Genetics 的市销率相对于同行较高并不困难。显然，股东们不愿意抛售可能面临更繁荣未来的股票。</p>
<h2>最终结论</h2>
<p>仅仅使用市销率来判断您是否应该出售股票并不明智，但它可以作为公司未来前景的实用指南。</p>
<p>我们对 Fulgent Genetics 的分析显示，其市销率仍然高于同行，基于其强劲的未来收入。目前，股东们对市销率感到满意，因为他们相当有信心未来的收入不会受到威胁。除非这些条件发生变化，否则他们将继续为股价提供强有力的支持。</p>
<p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>Fulgent Genetics 的 2 个警告信号</strong>（其中 1 个是重要的！）您应该了解。</p>
<p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>

FLGT

<p>Fulgent Genetics, Inc.（纳斯达克代码：FLGT）的市销率（P/S）为 2.1 倍，高于许多医疗行业的公司，其中近一半的公司市销率低于 1 倍。尽管最近的收入增长为 4.3%，但该公司在三年内的收入却下降了 67%。分析师预测明年的收入增长将达到 11%，超过行业平均水平的 7.7%。高市销率反映了市场对未来收入增长的信心，尽管仍存在潜在风险，包括为该公司识别出的两个警示信号</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value"/></p>
<p>NasdaqGM:FLGT 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>纳斯达克 GM:FLGT 1 年股价与公允价值</p>
</div><p>Explore Fulgent Genetics's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索 Fulgent Genetics 的社区公允价值并选择您的观点</p>
</div><p>When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or &#34;P/S&#34;) below 1x, you may consider <strong>Fulgent Genetics, Inc.</strong>(NASDAQ:FLGT) as a stock to potentially avoid with its 2.1x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>当美国医疗行业近一半的公司市销率（或称&#34;P/S&#34;）低于 1 倍时，您可能会考虑 <strong>Fulgent Genetics, Inc.</strong>（NASDAQ:FLGT）作为一个潜在的避开对象，因为其市销率为 2.1 倍。然而，市销率可能高是有原因的，需要进一步调查以确定其是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>View our latest analysis for Fulgent Genetics</p>
<div class="lb-trans"><p>查看我们对 Fulgent Genetics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719" alt="" original-src="https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719"/></p>
<p>NasdaqGM:FLGT Price to Sales Ratio vs Industry August 6th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:FLGT 市销率与行业比较 2025 年 8 月 6 日</p>
</div><h3>How Fulgent Genetics Has Been Performing</h3>
<div class="lb-trans"><h3>Fulgent Genetics 的表现如何</h3>
</div><p>Recent times haven't been great for Fulgent Genetics as its revenue has been rising slower than most other companies. Perhaps the market is expecting future revenue performance to undergo a reversal of fortunes, which has elevated the P/S ratio. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>最近一段时间，Fulgent Genetics 的表现并不理想，因为其收入增长速度低于大多数其他公司。也许市场预计未来的收入表现将会逆转，这提升了市销率。然而，如果情况并非如此，投资者可能会发现自己为该股票支付了过高的价格。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Fulgent Genetics.</p>
<div class="lb-trans"><p>如果您想了解分析师对未来的预测，您应该查看我们关于 Fulgent Genetics 的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Enough Revenue Growth Forecasted For Fulgent Genetics?</h2>
<div class="lb-trans"><h2>Fulgent Genetics 的收入增长预测是否足够？</h2>
</div><p>In order to justify its P/S ratio, Fulgent Genetics would need to produce impressive growth in excess of the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，Fulgent Genetics 需要实现超过行业的显著增长。</p>
</div><p>If we review the last year of revenue growth, the company posted a worthy increase of 4.3%. Still, lamentably revenue has fallen 67% in aggregate from three years ago, which is disappointing. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顾过去一年的收入增长，公司实现了 4.3% 的可观增长。然而，遗憾的是，收入与三年前相比总共下降了 67%，这令人失望。因此，不幸的是，我们必须承认公司在这段时间内未能很好地实现收入增长。</p>
</div><p>Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 11% over the next year. With the industry only predicted to deliver 7.7%, the company is positioned for a stronger revenue result.</p>
<div class="lb-trans"><p>展望未来，覆盖该公司的三位分析师的估计显示，收入在明年应增长 11%。而行业仅预测增长 7.7%，公司有望实现更强的收入结果。</p>
</div><p>With this in mind, it's not hard to understand why Fulgent Genetics' P/S is high relative to its industry peers. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.</p>
<div class="lb-trans"><p>考虑到这一点，理解为什么 Fulgent Genetics 的市销率相对于同行较高并不困难。显然，股东们不愿意抛售可能面临更繁荣未来的股票。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最终结论</h2>
</div><p>Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>仅仅使用市销率来判断您是否应该出售股票并不明智，但它可以作为公司未来前景的实用指南。</p>
</div><p>Our look into Fulgent Genetics shows that its P/S ratio remains high on the merit of its strong future revenues. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.</p>
<div class="lb-trans"><p>我们对 Fulgent Genetics 的分析显示，其市销率仍然高于同行，基于其强劲的未来收入。目前，股东们对市销率感到满意，因为他们相当有信心未来的收入不会受到威胁。除非这些条件发生变化，否则他们将继续为股价提供强有力的支持。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>2 warning signs for Fulgent Genetics</strong> (of which 1 is significant!) you should know about.</p>
<div class="lb-trans"><p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>Fulgent Genetics 的 2 个警告信号</strong>（其中 1 个是重要的！）您应该了解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>
</div>

Fulgent Genetics, Inc.（纳斯达克股票代码：FLGT）的市销率符合市场预期